Table 3 Maintenance immunosuppressant treatment and annual relapse rate in children with MNOS.
No | Immunos Uppressant | Duration of immunosuppressant use | Relapse rate per Year before immunosuppressant use | Annual relapse Rate after immunosuppressant use | Maintenance Time (month) | Annual Relapse rate | |
|---|---|---|---|---|---|---|---|
Number of episodes | Time since the first onset (month) | ||||||
1 | MFM | 2 | 5 | 2.4 | 0 | 14 | 0.2 |
2 | RTX | 2 | 3 | 4 | 0 | 0.25 | |
3 | RTX | 2 | 4 | 3 | 0.3 | 14 | 0.5 |
4 | MFM | 3 | 12 | 2 | 0.5 | 0.75 | |
5 | RTX and MFM mycophenolate mofetil | 3 | 10 | 2.4 | 0 | 0.5 | |
6 | AZA | 2 | 24 | 0.5 | 0 | 19 | 0.2 |
7 | MFM | 2 | 3 | 4 | 0 | 35 | 0.25 |
8 | / | / | / | / | / | / | 0.33 |
9 | / | / | / | / | / | / | / |
10 | RTX intravenous immunoglobulin | 2 | 40 | 0.3 | 0.5 | 12 | 0.57 |
11 | MFM | 2 | 5 | 2.4 | 0 | 12 | 0.44 |
12 | / | / | / | / | / | / | / |
13 | RTX | 2 | 6 | 2 | 0 | 5 | 1 |
